摘要
目的分析程序性死亡受体1(programmed cell death protein 1,PD-1)治疗晚期原发性肝癌患者的临床疗效及安全性。方法选取2022年6月至2024年6月通化市中心医院接收的160例晚期原发性肝癌患者作为研究对象,根据治疗方案不同分为两组,各80例。对照组接受甲磺酸阿帕替尼治疗,实验组行PD-1联合甲磺酸阿帕替尼治疗,比较两组临床疗效、肿瘤标志物、肿瘤浸润指标及不良反应发生情况。结果实验组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,实验组甲胎蛋白、糖类抗原19-9、癌抗原125水平均低于对照组,差异有统计学意义(P<0.05);治疗后,实验组血管内皮生长因子、磷脂酰肌醇蛋白多糖-3、血清高尔基体蛋白73水平均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论PD-1治疗晚期原发性肝癌疗效显著,且安全性高,值得临床推广应用。
Objective To analyze the clinical efficacy and safety evaluation of programmed cell death protein 1(PD-1)in patients with advanced primary liver cancer.Methods A total of 160 patients with advanced primary liver cancer admitted to Tonghua Central Hospital from June 2022 to June 2024 were selected as the study subjects,they were divided into the two groups according to different treatment plans,with 80 cases in each group.The control group was treated with apatinib mesylate,and the experimental group was treated with PD-1 combined with apatinib mesylate.The clinical efficacy,tumor markers,tumor infiltration index and adverse reactions were compared between the two groups.Results The total effective rate in the experimental group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of alpha-fetoprotein,carbohydrate antigen 19-9 and cancer antigen 125 in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of vascular endothelial growth factor,glycan-3 and serum golgi protein 73 in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion PD-1 is effective and safe in the treatment of advanced primary liver cancer,which is worthy of clinical promotion and application.
作者
王君
封俊阳
岳小玲
崔晓旭
秦静
WANG Jun;FENG Junyang;YUE Xiaoling;CUI Xiaoxu;QIN Jing(Tonghua Central Hospital,Tonghua,Jilin,134001,China;Tonghua Hospital of Traditional Chinese Medicine,Tonghua,Jilin,134001,China)
出处
《当代医学》
2025年第8期66-69,共4页
Contemporary Medicine
关键词
程序性死亡受体1
晚期原发性肝癌
临床疗效
预后
Programmed cell death protein 1
Advanced primary liver cancer
Clinical efficacy
Prognosis
